Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2021 / 05:10PM GMT
Release Date Price: $33.18 (-0.33%)
Mark Alan Breidenbach
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Hi, everyone. Thanks so much for joining us on day 2 of Oppenheimer's 31st Annual Healthcare Conference. My name is Mark Breidenbach. I'm part of Oppenheimer's biotech equity research team. And this afternoon, I'm pleased to be hosting a fireside chat with Iovance, which is developing autologous cell therapies for cancer. And we're joined by the company's CEO, Maria Fardis. We'll be sure to try to leave a few minutes at the end for Q&A. So I would encourage anyone in the audience who has a question to make use of the question box underneath your video.

So thank you for joining us, everyone, and let's go ahead and get started.

Maria, for the uninitiated, maybe you can give us a very brief introduction to the company and its core technology platform and a very quick overview of its lead programs.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Absolutely. Thank you, Mark, and thank you for hosting us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot